On June 30, 2026, MacroGenics, Inc. completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC. The transaction included facilities in Rockville and Frederick, Maryland, excluding research assets. MacroGenics received $122.5 million before transaction fees and expenses, subject to customary post-closing adjustments. The company operates in the biotechnology industry, focusing on the development of therapeutic antibodies.
